Read without an account

Explore the latest available issue and the archive. Employer links open directly on the hiring company’s website.

Account service update
Latest issue
Abstract map of clinical evidence moving through RNA, regulatory and oncology pathways
September 30, 20266 minute read

Clinical / Regulatory / Careers

Clinical evidence advances. Execution work broadens.

Dyne reports longer-term DM1 data as Wave, Pharmazz and Candel move RNA, neurotrauma and oncology programs forward.

4

verified developments

5

public boards refreshed

5

current openings

Read the latest report

Previous reports

Review the biotech job market over time

Abstract map of capital and clinical pathways converging across life-sciences programs
Tuesday issue
September 29, 20266 minute read

Capital converges. Development work gets specific.

AstraZeneca backs Summit's oncology combinations while Novo Nordisk and Aptadir fund new programs and Lilly sharpens an oral GLP-1 comparison.

Read report
Abstract map of four evidence pathways converging across a life-sciences decision landscape
Monday issue
September 28, 20266 minute read

Pivotal readouts move. Portfolios find their footing.

Mirum and Kodiak report pivotal trial results as Zymeworks and OSE clarify their next operating steps.

Read report
Two scientists working together at a laboratory bench
Thursday issue
September 17, 20267 minute read

Clinical programs gain backing. Thursday hiring rises.

Lisata acquires Marea and signs a $225 million financing agreement while Thursday's active biopharma job sample rises 22.6% from last week.

Read report
Two life-sciences colleagues reviewing an unlabeled vessel in a laboratory
Wednesday issue
September 16, 20267 minute read

Investment plans grow. Specialized trials advance.

Reckitt maps up to $600 million for U.S. R&D and manufacturing while the Wednesday hiring sample rises 10.7% from last week.

Read report
Three life-sciences professionals reviewing evidence together in a contemporary laboratory
Tuesday issue
September 15, 20268 minute read

Programs narrow. Tuesday hiring rebounds.

Sionna cuts 46% of its workforce while 703 active biopharma opportunities added before cutoff are 82.1% above last Tuesday.

Read report
Two life-sciences researchers reviewing a molecular model and evidence in a contemporary laboratory
Monday issue
September 14, 20267 minute read

Trial evidence sharpens. Monday hiring accelerates.

Enhertu improves progression-free survival while 131 active biopharma opportunities added before cutoff are 89.9% above last Monday.

Read report
Two life-sciences researchers reviewing an unlabeled vial beside a translucent lung model
Sunday issue
September 13, 20265 minute read

Phase 3 evidence lands. Sunday hiring rises.

Roche reports a Tam-Peli survival benefit while 494 active biopharma opportunities added before cutoff are 75.2% above last Sunday.

Read report
Two oncology researchers examining an unlabeled vial and a molecular model in a translational laboratory
Saturday issue
September 12, 20266 minute read

Dose selection advances. Saturday hiring jumps.

SystImmune selects an iza-bren Phase 3 dose while 485 active biopharma opportunities added before cutoff are 86.5% above last Saturday.

Read report
Two bioprocess scientists examining a sample beside analytical and manufacturing equipment
Friday issue
September 11, 20267 minute read

Development narrows. Friday hiring expands.

Immutep resets efti development and manufacturing while 772 active biopharma opportunities added before cutoff are 24.3% above last Friday.

Read report
Two life-sciences researchers beside stainless-steel manufacturing equipment in a modern facility
Thursday issue
September 10, 20267 minute read

Capacity expands. Thursday hiring accelerates.

Lonza plans a commercial spray-drying facility in Bend with more than 80 initial jobs; 818 active biopharma opportunities added before cutoff are 42.3% above last Thursday.

Read report
Two research scientists reviewing an assay in a bright contemporary laboratory
Wednesday issue
September 9, 20267 minute read

Research capacity opens. Wednesday hiring accelerates.

Gilead opens a 182,000-square-foot Foster City research center; 887 active biopharma opportunities added before cutoff put Wednesday volume 24.1% above last week.

Read report
A bioprocess engineer inspecting single-use bioreactors in a bright manufacturing suite
Tuesday issue
September 8, 20267 minute read

Capacity advances. Tuesday hiring cools.

Sandoz plans a $300 million biosimilar facility while 440 active biopharma opportunities added before cutoff trail last Tuesday by 19.7%.

Read report
Three adult clinical researchers reviewing pediatric growth evidence in a modern laboratory
Monday issue
September 7, 20267 minute read

Pediatric evidence lands. Monday hiring accelerates.

Novo Nordisk reports first STEP Young Phase 3 results while 81 active biopharma opportunities added before cutoff lift Monday volume 52.8%.

Read report
Three respiratory-medicine professionals reviewing clinical evidence beside a lung model
Sunday issue
September 6, 20265 minute read

A pulmonary readout nears. Sunday hiring expands.

Pulmovant schedules Phase 2 PHocus topline results for September 8 while 406 active biopharma opportunities added before cutoff lift Sunday volume 78.9%.

Read report
Three life-sciences professionals reviewing evidence around a table with a heart model
Saturday issue
September 5, 20267 minute read

A pivotal trial misses. A launch pathway opens.

Novartis reports a Phase III miss while an FDA-approved therapy-and-diagnostic pathway and 312 newly added opportunities keep execution broad.

Read report
Two sterile manufacturing professionals monitoring an enclosed vial filling line
Friday issue
September 4, 20267 minute read

Sterile capacity opens. Friday hiring holds steady.

Curia opens a $200 million fill-finish expansion while 770 active biopharma opportunities added before cutoff remain near last Friday.

Read report
A cross-functional biopharma team reviewing clinical evidence beside manufacturing equipment
Thursday issue
September 3, 20267 minute read

A pivotal miss brings a review. Specialized hiring rises.

Ultragenyx plans an expense review after Aspire misses while 742 active biopharma opportunities added before cutoff lift Thursday volume 60.3%.

Read report
A small cross-functional life-sciences team reviewing samples and execution plans in a modern laboratory
Wednesday issue
September 2, 20266 minute read

Biotech contracts. Specialized work keeps moving.

TScan cuts about 75% of its workforce while 901 active biopharma opportunities added before cutoff lift Wednesday volume 67.2%.

Read report
A cross-functional biopharma team reviewing samples and execution plans in a modern laboratory workspace
Tuesday issue
September 1, 20267 minute read

Evidence narrows. Execution work widens.

Alumis reports a mixed lupus readout while 730 active biopharma opportunities added before cutoff lift Tuesday volume 40.1%.

Read report
A cross-functional biopharma team reviewing regulatory and launch-readiness plans in a formulation workspace
Monday issue
August 31, 20267 minute read

Regulatory work advances. Specialized hiring stays precise.

Palvella completes an NDA submission while 75 active biopharma opportunities added before cutoff lift Monday volume 25%.

Read report
A cardiovascular drug-development team reviewing clinical evidence in a modern translational medicine workspace
Sunday issue
August 30, 20265 minute read

Cardiovascular evidence deepens. Specialized work stays broad.

Cytokinetics leads three ESC evidence updates while 344 active biopharma opportunities added before cutoff lift Sunday volume 21.1%.

Read report
A cross-functional life-sciences team reviewing laboratory and operations plans in a modern workspace
Saturday issue
August 29, 20266 minute read

Operations change shape. Specialized hiring keeps moving.

Trinity Biotech's operating-model shift leads four developments while 316 active biopharma opportunities added before cutoff lift Saturday volume 47%.

Read report
A process engineer and quality specialist reviewing plans beside biopharmaceutical manufacturing equipment
Friday issue
August 28, 20267 minute read

Capacity gets funded. Specialized work surges.

Evonik's planned Vancouver GMP expansion leads five developments while 953 active biopharma opportunities added before cutoff widen the execution signal.

Read report
Two biopharmaceutical professionals reviewing launch operations beside manufacturing equipment
Thursday issue
August 27, 20267 minute read

Approval arrives. Execution moves into launch.

Revolution Medicines' first broad RAS approval leads five developments while 696 active biopharma opportunities added before cutoff show broad execution demand.

Read report
Biologics manufacturing professionals reviewing process work beside stainless-steel equipment
Wednesday issue
August 26, 20267 minute read

Biologics capacity lands. Specialized work widens.

Elanco's completed Kansas expansion leads five developments while 768 active biopharma opportunities added before cutoff show broad specialized demand.

Read report
Two biopharmaceutical manufacturing operators checking stainless-steel process equipment
Tuesday issue
August 25, 20267 minute read

Commercial readiness arrives. Trial work scales.

Cambrex's inspection milestone leads five developments while 684 active biopharma opportunities added before cutoff show broad execution demand.

Read report
Two laboratory scientists preparing a blood sample beside a clinical analyzer
Monday issue
August 24, 20267 minute read

A blood assay clears. Trial execution accelerates.

Roche's newly cleared pTau217 assay leads five developments while 88 active biopharma roles added before cutoff keep the execution signal broad.

Read report
A bioprocess scientist checking production equipment in a warm, modern laboratory
Sunday issue
August 23, 20265 minute read

One IND moves. Specialized hiring doesn't wait.

Orum's FDA clearance leads a quiet Sunday news cycle while 377 active biopharma opportunities added before cutoff show broad execution demand.

Read report
A laboratory operations professional checking analytical equipment on a quiet morning
Saturday issue
August 22, 20265 minute read

Twenty hires break the quiet. Specialized work stays visible.

Iovance's completed hiring signal leads a quieter news window, alongside tools-sector continuity, a small clinical-stage financing, and broad Saturday hiring.

Read report
Two biopharma professionals reviewing vial-process data in a clean manufacturing setting
Friday issue
August 21, 20266 minute read

The route changes. Readiness keeps moving.

Scholar Rock's fill-finish pivot leads a day of milestone-linked capital, an Alzheimer's blood-test clearance, transplant evidence, and hiring.

Read report
Two scientists reviewing process data beside biopharmaceutical manufacturing equipment
Thursday issue
August 20, 20267 minute read

Capital clears the runway. Capability follows.

Amylyx's upsized offering leads a day of concrete execution signals in synthesis capacity, antibody discovery, vaccine CMC, and hiring.

Read report
A technician commissioning process equipment inside a new biomanufacturing facility
Wednesday issue
August 19, 20267 minute read

The build reaches the beam. Hiring broadens.

A North Carolina manufacturing milestone leads a day that also brought pivotal oncology data, a new AI-biotech launch, and a clinical-stage licensing move.

Read report
Biotechnology scientists reviewing analytical results in a modern laboratory
Tuesday issue
August 18, 20266 minute read

Biotech builds, cuts, and advances.

New analytical capacity, manufacturing investment, pipeline progress, and post-deal restructuring are reshaping where biotech opportunities appear.

Read report
Life science researchers working together in a biotechnology laboratory
Monday issue
August 17, 20266 minute read

Biopharma resets. Specialized hiring holds.

Clinical setbacks and acquisition-driven cuts shape the day, while biotech and biopharma employers continue recruiting in statistics, regulatory, manufacturing, quality, and cell therapy.

Read report
A life science professional checking bioprocess equipment on a quiet morning
Sunday issue
August 16, 20265 minute read

Weekend hiring stays steady as regulatory momentum builds.

The Sunday biotech job market was quieter, not stalled, with continued demand across clinical operations, laboratory systems, manufacturing, and digital health.

Read report

Understand

Know what changed

Concise biotech reporting connects clinical, regulatory, and workforce developments.

Focus

See where hiring moves

Biotech hiring signals highlight the functions, employers, and locations worth watching.

Act

Explore opportunities

Follow direct employer links and check the current requirements and availability.